The brain metastasis therapeutics market is expected to advance at a CAGR of 7.8% during the forecast period. The valuation of the market as of 2023 is US$ 3,269.8 million. The market is expected to be valued at US$ 6,915.2 million by 2033.
An increase in cancer cases, especially cerebrum malignancy, improving medical infrastructure, and many other activities are expected to increase the demand for brain metastasis therapeutics during the forecast period.
| Report Attribute | Details |
|---|---|
| Brain Metastasis Therapeutics Market Valuation in 2023 | US$ 3,269.8 million |
| Brain Metastasis Therapeutics Market Anticipated Value (2033) | US$ 6,915.2 million |
| Brain Metastasis Therapeutics Market Projected Growth Rate (2023 to 2033) | 7.8% |
Brain metastasis is typically cancer due to the spread of cancerous cells to the brain. Brain metastasis is more common as compared to primary brain cancer. Some known brain metastasis causes include a rapid spread in the cancer cells due to breast cancer, lung cancer, melanoma, renal cell carcinoma, and colon cancer.
The brain metastasis diagnosis is usually made using CAT/CT scan or MRI. Thanks to the increased penetration of these services, the diagnosis can be made in no time, and the patient can undergo the necessary treatment.
The diagnosis and rapid technological advancements have allowed the patient to undergo treatment within a few weeks, helping him lead an everyday life. This is anticipated to increase the demand for brain metastasis therapeutics during the forecast period.
Even the stats indicate that there might be an increase in the application of brain metastasis therapeutics in the coming times. The historical CAGR for the market was 5.1%, and the anticipated CAGR for the forecast period is 7.8%. The increase in forecast CAGR compared to the historical CAGR is undoubtedly projected to be instrumental in transforming lives for good.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increase in Cancer Cases:
A survey conducted by WHO found that cancer was the leading cause of death worldwide in 2020, and around 10 million people died of cancer. The most common types of cancer recorded were breast cancer (2.26 million cases) and lung cancer (2.21 million cases).
When cancer develops in some body parts, it gradually spreads to other parts of the body, reaching the brain and causing brain metastasis. Because of this, the demand for brain metastasis therapeutics is expected to increase.
Efficient Medical Infrastructure:
There has been a tremendous improvement in the medical infrastructure. This is mainly because of the evolving technology. This evolution has allowed doctors and physicians to work synchronously and carry out medical operations effectively. Moreover, the evolution of 3D printing has made it easier to locate the affected area in the brain with higher precision and clarity.
Apart from all this, the biggest boon is the reduced risk and recovery time. Because of technological innovations, treatments like laser surgery and other medical procedures are now less invasive. This is anticipated to increase the brain metastasis therapeutics market share.
High cost of treatment: The brain metastasis therapeutics treatment is quite costly, and despite wanting to avail of the service, many people are not able to take up the treatment, as a result of which their condition worsens.
Side effects: The biggest restraint that is plaguing the brain metastasis therapeutics market is the side effects that the patient has to face during and after the treatment. Some of the side effects include vomiting, weakness, seizures, etc.
Principal Consultant
Of late, there has been an increasing adoption of Ayurveda and Yoga. These are believed to be highly harmless methods for resolving health issues. The time taken to show visible effects might be high, but experts are of the opinion that the effects are long-lasting.
If we talk about Yoga, there is no side effect involved, as it involves experimenting entirely with the body and focusing on the breathing pattern. Many scientists believe that cancer results from inadequate oxygen flow to certain parts of the body, and Yoga helps resolve that.
However, Ayurveda, on the other is more about treating health issues using ancient Indian techniques, which mainly involves the usage of herbs and certain kinds of spices. In many cases, Ayurveda has successfully delivered the required results for almost any kind of patient. Thus, the increased adoption of Ayurveda and Yoga might negatively impact the brain metastasis therapeutics industry outlook.
| Region | North America |
|---|---|
| Market Share % (2022) | 35% |
The North American brain metastasis therapeutics industry, which currently has a market share of around 35%, is expected to be one of the largest markets during the forecast period.
A study conducted in 2018 by ‘The Cancer Atlas’ found that there were nearly 1.9 million new cancer cases in 2018, apart from the existing ones. Moreover, North America is also meant for people who suffer from lifestyle diseases, and cancer is also believed to be caused by lifestyle diseases in many cases. With so many health-related issues affecting the region, it is anticipated that brain metastasis therapeutics adoption trends is expected to positively influence the region.
| Region | Europe |
|---|---|
| Market Share % (2022) | 24.5% |
The European brain metastasis therapeutics industry, which has a share of 24.5%, is expected to be one of the most significant regions during the forecast period.
The region is meant for people to take proactive steps if they get a hint regarding any health-related issues. Moreover, people in this region can afford various health services because of the active involvement of the government in such activities. Moreover, the region has witnessed higher technological innovations, which have made brain metastasis therapeutics treatment much more efficient in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There is not much happening in the start-up ecosystem of the brain metastasis therapeutics industry, and the market is dominated only by the players who have been serving this niche for a long time.
But, with so many angel investors looking for entrepreneurs willing to start a business in this niche, this niche represents many opportunities. Moreover, with rapid technological advancements in the medical sector, start-ups can make the best use of this situation and can come up with innovative ways to cure such health issues.
The key players in the brain metastasis therapeutics market are looking for ways to further diversify their portfolios. They are doing this through mergers, acquisitions, or opening new centers. Additionally, these players have also been involved in demergers to stop operating in markets that are of no use.
Some of the key players are Bayer AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., Eli Lilly & Company, Novartis AG, GlaxoSmithKline, Merck & Co., Inc., AstraZeneca, and AngioChem Inc.
Some of the recent developments are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The brain metastasis therapeutics market is set to reach US$ 3,269.8 million in 2023, with sales potentially surging to US$ 6,915.2 million by 2033, exhibiting a 7.8% CAGR.
The global brain metastasis therapeutics market registered a CAGR of 5.1% between 2018 and 2022.
Advancements in targeted therapies, precision medicine, and neuroimaging techniques significantly impact brain metastasis therapeutics market growth.
North America stands as a prominent player in the brain metastasis therapeutics landscape, owing to its strong clinical trial infrastructure.
Radiation therapy prevails in brain metastasis therapeutics, excelling in targeted treatment for metastatic brain tumors.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 5.3.1. Radiation Therapy 5.3.2. Chemotherapy 5.3.3. Targeted Therapy 5.3.4. Anticonvulsants 5.3.5. Corticosteroids 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033 6.3.1. Cancer Hospitals 6.3.2. Clinics 6.3.3. Cancer Research Centers 6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By End Use 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By End Use 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By End Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By End Use 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Treatment Type 10.2.3. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By End Use 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Treatment Type 11.2.3. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By End Use 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Treatment Type 12.2.3. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By End Use 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment Type 13.2.3. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By End Use 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Type 14.2.3. By End Use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By End Use 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment Type 15.1.2.2. By End Use 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment Type 15.2.2.2. By End Use 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment Type 15.3.2.2. By End Use 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment Type 15.4.2.2. By End Use 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment Type 15.5.2.2. By End Use 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment Type 15.6.2.2. By End Use 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment Type 15.7.2.2. By End Use 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment Type 15.8.2.2. By End Use 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment Type 15.9.2.2. By End Use 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment Type 15.10.2.2. By End Use 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment Type 15.11.2.2. By End Use 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment Type 15.12.2.2. By End Use 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment Type 15.13.2.2. By End Use 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment Type 15.14.2.2. By End Use 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment Type 15.15.2.2. By End Use 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment Type 15.16.2.2. By End Use 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment Type 15.17.2.2. By End Use 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment Type 15.18.2.2. By End Use 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment Type 15.19.2.2. By End Use 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment Type 15.20.2.2. By End Use 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment Type 15.21.2.2. By End Use 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Treatment Type 15.22.2.2. By End Use 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Treatment Type 15.23.2.2. By End Use 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Type 16.3.3. By End Use 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Bayer AG 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Pfizer Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Sanofi 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. F. Hoffmann-La Roche Ltd. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Eli Lilly & Company 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Novartis AG 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. GlaxoSmithKline 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Merck & Co. Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. AstraZeneca 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. AngioChem Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Brain Metastasis Therapeutics Market
